Impact of Sofosbuvir/Daclatasvir treatment on glycemic control and lipid profile in diabetic patients with chronic hepatitis C

Abstract Background and aim Limited data on the effects of direct-acting antiviral (DAA) drugs on glycemic control and lipid profiles in chronic hepatitis C (CHC) patients with type 2 diabetes mellitus (T2DM). Methods One hundred fifty-one treatment-naïve CHC patients with T2DM, not on insulin and w...

Full description

Bibliographic Details
Published in:Egyptian Liver Journal
Main Authors: Tamer Fouad, Ahmed Abd Elraouf, Hassan Elshenawy, Gamal Badra, Heba Abd Allah, Ahmed Attia
Format: Article
Language:English
Published: SpringerOpen 2025-07-01
Subjects:
DAAs
Sofosbuvir
Daclatasvir
Hepatitis C
HOMA-IR
HbA1C
Online Access:https://doi.org/10.1186/s43066-025-00436-w

Internet

https://doi.org/10.1186/s43066-025-00436-w

Similar Items